论文部分内容阅读
前几期我们讲的他汀类药物是目前临床上最常见的调脂药物,然而在临床实践中,许多患者在接受了较大剂量他汀类药物治疗后其胆固醇水平仍不能达到预期的目标值以下,另有一些患者由于种种原因(种族、不良反应、药物相互作用等)不能耐受他汀治疗,这已成为提高血脂达标率的重要羁绊。中国第二次血脂治疗现状调研结果显示,高危和极高危心血管病患者低密度脂蛋白胆固醇(LDL-C)达标率均很低,因此我们应采取更多的有效手段对血脂异常进行干预。随着这样的局面,调脂“新星”依折
The statins we talked about earlier periods are by far the most common lipid-lowering drugs in the clinic, yet in clinical practice many patients do not achieve the expected cholesterol below their target value after receiving larger doses of statins In addition, some patients can not tolerate statin treatment due to various reasons (race, adverse reactions, drug interactions, etc.), which has become an important bond to raise blood fat compliance rate. The results of the study on the status of second blood lipids in China showed that the rate of low-density lipoprotein cholesterol (LDL-C) in patients with cardiovascular disease at high risk and very high risk was very low, so we should take more effective measures to interfere with dyslipidemia. With this situation, lipid-lowering “nova ” according to the fold